Enhanced pairing.
Unlocking potential.

Photys Therapeutics is a proximity-based therapeutics company advancing a new generation of targeted protein modulation medicines. Through its proprietary PHICS™ and tPRIME™ platforms, together with deep expertise in PROTACs, Photys is building a pipeline of differentiated therapies for autoimmune, inflammatory, oncology, and cardiometabolic diseases.

LEAD CLINICAL PROGRAM

PHT-776

CLINICAL

PHT-776: Oral IRAK4-targeted PROTAC
Stage: Clinical
Focus: Autoimmune and inflammatory diseases
Differentiation: High oral bioavailability; preclinical data demonstrated potent efficacy and a broad safety window, with no observed cardiovascular effects

PHICS PROGRAM

Undiclosed targets partnered with Novo
Stage: Preclinical
Focus: Cardiometabolic diseases

PHICS™

PRECLINICAL

tPRIME PROGRAM

Target: p53 Y220C
Stage: Preclinical
Focus: Oncology

tPRIME™

PRECLINICAL

Enhanced pairing.
Unlocking potential.

Photys Therapeutics is a proximity-based therapeutics company advancing a new generation of targeted protein modulation medicines. Through its proprietary PHICS™ and tPRIME™ platforms, together with deep expertise in PROTACs, Photys is building a pipeline of differentiated therapies for autoimmune, inflammatory, oncology, and cardiometabolic diseases.

Lead Clinical Program

PHT-776: Oral IRAK4-targeted PROTAC
Stage: Clinical
Focus: Autoimmune and inflammatory diseases
Differentiation: High oral bioavailability; preclinical data demonstrated potent efficacy and a broad safety window, with no observed cardiovascular effects

PHICS Program

Undiclosed targets partnered with Novo
Stage: Preclinical
Focus: Cardiometabolic diseases

tPRIME Program

Target: p53 Y220C
Stage: Preclinical
Focus: Oncology

Enhanced pairing.
Unlocking potential.

Photys Therapeutics is a proximity-based therapeutics company advancing a new generation of targeted protein modulation medicines. Through its proprietary PHICS™ and tPRIME™ platforms, together with deep expertise in PROTACs, Photys is building a pipeline of differentiated therapies for autoimmune, inflammatory, oncology, and cardiometabolic diseases.

PHT-776

CLINICAL

PHT-776: Oral IRAK4-targeted PROTAC
Stage: Clinical
Focus: Autoimmune and inflammatory diseases
Differentiation: High oral bioavailability; preclinical data demonstrated potent efficacy and a broad safety window, with no observed cardiovascular effects

PHT-776/HPB-143 was licensed from PolyMed Therapeutics, which continues to support the program’s development in China.

LEAD CLINICAL PROGRAM

PHICS PROGRAM

Undiclosed targets partnered with Novo
Stage: Preclinical
Focus: Cardiometabolic diseases

PHICS™

PRECLINICAL

tPRIME PROGRAM

Target: p53 Y220C
Stage: Preclinical
Focus: Oncology

tPRIME™

PRECLINICAL

Platforms

PLATFORMS

HETEROBIFUNCTIONAL MOLECULES
One molecular design. Three therapeutic platforms.

PROTAC

PROteolysis-TArgeting Chimera

PHICS™

PHosphorylation-Inducing Chimeric Small molecules

tPRIME™

targeted-PRoximity-Induced Modulator of Expression

Reprogram Protein Function

Control phosphorylation to activate, stabilize, relocate, or degrade proteins. Create new therapeutic possibilities by precisely rewiring protein behavior.

Restore Protective Proteins

Increase the expression of protective proteins that are underactive in disease. Replenish beneficial proteins without gene editing or gene therapy.

Eliminate Disease Drivers

Selectively remove disease-causing proteins through targeted degradation. Clinical-stage lead program: PHT-776, an oral IRAK4 degrader.

PLATFORMS

HETEROBIFUNCTIONAL MOLECULES

One molecular design. Three therapeutic platforms.

PHICS™

PHosphorylation-Inducing Chimeric Small molecule
----------------
Reprogram Protein Function

Control phosphorylation to activate, stabilize, relocate, or degrade proteins. Create new therapeutic possibilities by precisely rewiring protein behavior.

PIPELINE

Licensed from PolyMed Therapeutics

PIPELINE

Licensed from PolyMed Therapeutics

Our Team

TEAM

Photys is led by a team of highly experienced biotech executives with a track record of scientific, clinical, operational and business accomplishments.

Kazumi Shiosaki, PhD

Executive Chair

Shomir Ghosh, PhD

Interim Chief Scientific Officer

Lizzie Ngo, PhD

Interim Chief Operating Officer

Arian Pano, MD

Interim Chief Medical Officer

Head of Program Management

CLINICAL & SCIENTIFIC ADVISORS

Photys is fortunate to bring together an integrated set of world-class advisors that are providing critical input and review of all activities associated with the preclinical platform and programs as well as supporting the clinical and translational activities around PHT-776.

Kevin Leach, PhD, DABT

CLINICAL & SCIENTIFIC ADVISORS

Photys is fortunate to bring together an integrated set of world-class advisors that are providing critical input and review of all activities associated with the preclinical platform and programs as well as supporting the clinical and translational activities around PHT-776.

Kevin Leach, PhD, DABT